miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan
| العنوان: | miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan |
|---|---|
| المؤلفون: | Mogens Kruhøffer, Estrid Høgdall, Sabine Tejpar, Simona Rossi, Mette Karen Yilmaz, Benny Vittrup Jensen, Mauro Delorenzi, Julia S. Johansen, Per Pfeiffer, Dorte Nielsen, Jakob V. Schou |
| المصدر: | PLoS ONE, Vol 9, Iss 6, p e99886 (2014) Schou, J V, Rossi, S, Jensen, B V, Nielsen, D L, Pfeiffer, P, Høgdall, E, Yilmaz, M, Tejpar, S, Delorenzi, M, Kruhøffer, M & Johansen, J S 2014, ' miR-345 in Metastatic Colorectal Cancer : A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan ', P L o S One, vol. 9, no. 6, e99886 . https://doi.org/10.1371/journal.pone.0099886 Schou, J V, Rossi, S, Jensen, B V, Nielsen, D L, Pfeiffer, P, Høgdall, E, Yilmaz, M, Tejpar, S, Delorenzi, M, Kruhøffer, M & Johansen, J S 2014, ' miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan ', PLOS ONE, vol. 9, no. 6, e99886 . https://doi.org/10.1371/journal.pone.0099886 PLoS ONE Plos One, vol. 9, no. 6, pp. e99886 |
| بيانات النشر: | Public Library of Science (PLoS), 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Oncology, Male, Colorectal cancer, DNA Mutational Analysis, Cancer Treatment, Cetuximab, lcsh:Medicine, Kaplan-Meier Estimate, medicine.disease_cause, Pathology and Laboratory Medicine, Biochemistry, Antineoplastic Combined Chemotherapy Protocols, Gastrointestinal Cancers, Medicine and Health Sciences, lcsh:Science, Aged, 80 and over, education.field_of_study, Multidisciplinary, Hazard ratio, Middle Aged, 3. Good health, Gene Expression Regulation, Neoplastic, Treatment Outcome, Medical Microbiology, Female, KRAS, Colorectal Neoplasms, medicine.drug, Research Article, Adult, medicine.medical_specialty, Population, Immunology, Gastroenterology and Hepatology, Antibodies, Monoclonal, Humanized, Irinotecan, Microbiology, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), Antibody Therapy, Diagnostic Medicine, Internal medicine, Proto-Oncogene Proteins, Gastrointestinal Tumors, medicine, Biomarkers, Tumor, Humans, education, neoplasms, Aged, Proportional Hazards Models, Performance status, business.industry, lcsh:R, Cancer, Biology and Life Sciences, Cancers and Neoplasms, medicine.disease, digestive system diseases, MicroRNAs, Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Camptothecin/analogs & derivatives, Camptothecin/therapeutic use, Colorectal Neoplasms/blood, Colorectal Neoplasms/drug therapy, MicroRNAs/blood, MicroRNAs/genetics, Multivariate Analysis, Mutation/genetics, Proto-Oncogene Proteins/genetics, Tumor Markers, Biological/genetics, ras Proteins/genetics, Mutation, ras Proteins, Camptothecin, Clinical Immunology, lcsh:Q, business, Biomarkers |
| الوصف: | INTRODUCTION: MicroRNAs (miRNAs) have important regulatory functions in cellular processes and have shown promising potential as prognostic markers for disease outcome in patients with cancer. The aim of the present study was to find miRNA expression profiles in whole blood that were prognostic for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with cetuximab and irinotecan.METHODS: From 138 patients with mCRC in 3rd line therapy with cetuximab and irinotecan in a prospective phase II study, 738 pretreatment miRNAs were isolated and profiled from whole blood using the TaqMan MicroRNA Array v2.0. Mutation status of KRAS, BRAF, and PI3KCA was known.RESULTS: After Bonferroni adjustment, 6 miRNAs: (miR-345, miR-143, miR-34a*, miR-628-5p, miR-886-3p and miR-324-3p), were found associated with short OS. miR-345 was the strongest prognostic miRNA, significant in the full cohort and in the non-KRAS mutant population. miR-345, as a continuous variable in the full cohort, resulted in a hazard ratio (HR) of 2.38 per IQR (CI 95%: 1.8-3.1, P-value = 2.86e-07, Bonferroni adjusted, univariable analysis) and a HR = 1.75 per IQR (CI 95%: 1.24-2.48, P-Wald = 1.45e-03) in the multivariable analysis adjusted for gender, age, KRAS, PI3KCA and performance status. miR-345 was prognostic in progression-free survival (PFS) with a HR = 1.63 per IQR (CI 95%: 1.25-2.114, P-Wald = 2.92e-4) in the multivariable analysis. In addition, high miR-345 expression was associated with lack of response to treatment with cetuximab and irinotecan.CONCLUSION: We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1932-6203 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ebb1f483324d6363101365978430663 http://europepmc.org/articles/PMC4062472?pdf=render |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....7ebb1f483324d6363101365978430663 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|